Earnings History Data for Taysha Gene Therapies, Inc. (TSHA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Taysha Gene Therapies, Inc.

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-11-2024	AH		TSHA	Taysha Gene Therapies, Inc.	334.06	-0.09	-0.08	-0.13	Taysha Gene Therapies GAAP EPS of $1.78 beats by $1.87, revenue of $1.78M beats by $0.13M [11/13/2024 4:48 PM]	2.29	0.08 (3.85%)	2.00	-0.21 (-9.50%)	1.19 - 4.32	9,725,724	8,770,000	92,213
Taysha Gene Therapies GAAP EPS of $1.78 beats by $1.87, revenue of $1.78M beats by $0.13M [11/13/2024 4:48 PM] Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update [2024-11-13 04:01PM]
12-08-2024	PM		TSHA	Taysha Gene Therapies, Inc.	392.74	-0.09	-0.10	-0.38	Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.11M misses by $1.52M [8/12/2024 8:06 AM]	2.06	-0.03 (-1.67%)	2.05	-0.04 (-1.91%)	1.27 - 4.32	1,596,108	1,290,000	14,013
Taysha Gene Therapies GAAP EPS of -$0.09 beats by $0.01, revenue of $1.11M misses by $1.52M [8/12/2024 8:06 AM]
14-05-2024	AH		TSHA	Taysha Gene Therapies, Inc.	437.62	-0.10	-0.11	-0.28	Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.01, revenue of $3.41M beats by $0.85M [5/14/2024 4:10 PM]	3.08	0.52 (20.04%)	2.50	-0.07 (-2.72%)	0.50 - 3.89	4,558,902	1,430,000	18,977
Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset [5/14/2024 12:45 PM] Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.01, revenue of $3.41M beats by $0.85M [5/14/2024 4:10 PM]
19-03-2024	AH		TSHA	Taysha Gene Therapies, Inc.	430.01	0.35	0.00	-0.99	Taysha Gene Therapies GAAP EPS of -$0.96 beats by $0.47, revenue of $15.5M beats by $1.02M [3/19/2024 4:10 PM]	2.94	0.69 (30.67%)	2.89	0.64 (28.44%)	0.50 - 3.89	21,402,364	1,920,000	2,615,268
Taysha Gene Therapies GAAP EPS of -$0.96 beats by $0.47, revenue of $15.5M beats by $1.02M [3/19/2024 4:10 PM] Taysha Gene Therapies jumps after early data for Rett syndrome candidate [3/20/2024 8:15 AM]
14-11-2023	AH		TSHA	Taysha Gene Therapies, Inc.	281.38	-0.13	-0.13	-0.64	Taysha Gene Therapies GAAP EPS of -$0.93 misses by $0.76, revenue of $4.74M beats by $2.64M [11/14/2023 4:23 PM]	1.68	0.35 (26.32%)	1.49	0.16 (12.03%)	0.50 - 3.89	17,329,900	2,220,000	11,699
Taysha Gene Therapies GAAP EPS of -$0.93 misses by $0.76, revenue of $4.74M beats by $2.64M [11/14/2023 4:23 PM]
14-08-2023	PM		TSHA	Taysha Gene Therapies	45.00	-0.38	-0.31	0.00	Taysha Gene Therapies GAAP EPS of -$0.38, revenue of $2.39M [8/14/2023 9:51 AM]	2.11	1.37 (185.53%)	1.50	0.76 (102.98%)	0.50 - 4.63	124,442,285	200,000	22,799,515
Taysha Gene Therapies agrees on ~$150M private placement financing [8/14/2023 8:26 AM] Taysha Gene Therapies GAAP EPS of -$0.38, revenue of $2.39M [8/14/2023 9:51 AM] Taysha surges on private placement, early data from lead program [8/14/2023 11:56 AM]
11-05-2023	AH	After the close (May 11)	TSHA	Taysha Gene Therapies, Inc.	44.91	-0.28	-0.39	-1.31	Taysha Gene Therapies GAAP EPS of -$0.28 beats by $0.07, revenue of $4.71M beats by $3.58M [5/11/2023 4:44 PM]	0.6702	-0.04 (-5.47%)	0.75	0.04 (5.78%)	0.61 - 5.09	589,385	220,000	1,188
Taysha Gene Therapies GAAP EPS of -$0.28 beats by $0.07, revenue of $4.71M beats by $3.58M [5/11/2023 4:44 PM]
28-03-2023	AH	After the close (Mar 28)	TSHA	Taysha Gene Therapies, Inc.	66.81	-0.99	-0.41	-1.32	Taysha Gene Therapies GAAP EPS of -$0.99 misses by $0.70, revenue of $2.5M misses by $6.5M [3/28/2023 4:21 PM]	0.64	-0.01 (-1.84%)	0.68	0.03 (3.99%)	0.61 - 7.08	672,724	440,000	1,153
Taysha Gene Therapies GAAP EPS of -$0.99 misses by $0.70, revenue of $2.5M misses by $6.5M [3/28/2023 4:21 PM]
08-11-2022	PM	7:00 AM ET (Nov 8)	TSHA	Taysha Gene Therapies, Inc.	94.30	-0.64	-0.88	-1.35	Taysha Gene Therapies GAAP EPS of -$0.64 beats by $0.15 [11/8/2022 7:13 AM]	2.22	0.22 (11.00%)	2.09	0.09 (4.50%)	1.35 - 16.08	2,629,825	12,870,000	345,611
Taysha Gene Therapies GAAP EPS of -$0.64 beats by $0.15 [11/8/2022 7:13 AM] Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update [Nov-08-22 07:00AM]
11-08-2022	PM	7:00 AM ET (Aug 11)	TSHA	Taysha Gene Therapies	195.00	-0.84	-1.05	0.00	Taysha Gene Therapies GAAP EPS of -$0.84 beats by $0.13 [8/11/2022 7:17 AM]	3.95	-0.93 (-19.06%)	4.88	0.0 (0.00%)	2.33 - 21.90	344,644	90,000	780
Taysha Gene Therapies GAAP EPS of -$0.84 beats by $0.13 [8/11/2022 7:17 AM]
16-05-2022	PM	7:00 AM ET (May 16)	TSHA	Taysha Gene Therapies, Inc.	124.26	-1.31	-1.03	-0.87	Taysha Gene Therapies GAAP EPS of -$1.31 misses by $0.24 [5/16/2022 7:04 AM]	3.34	-0.10 (-2.85%)	3.46	0.02 (0.58%)	2.69 - 26.99	371,347	260,000	549
Taysha Gene Therapies GAAP EPS of -$1.31 misses by $0.24 [5/16/2022 7:04 AM] Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update [May-16-22 07:00AM]
31-03-2022	PM	7:00 AM ET (Mar 31)	TSHA	Taysha Gene Therapies, Inc.	223.15	-1.32	-1.21	0.00	Taysha Gene Therapies GAAP EPS of -$1.32 misses by $0.10 [3/31/2022 7:01 AM]	6.51	0.36 (5.85%)	6.15	0.0 (0.00%)	5.00 - 27.00	274,060	200,000	281
Taysha Gene Therapies GAAP EPS of -$1.32 misses by $0.10 [3/31/2022 7:01 AM] Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update [Mar-31-22 07:00AM] Why this Dallas biotech firm is cutting roughly 35% of its headcount [Mar-31-22 06:29PM] Taysha Gene Therapies, Inc. (TSHA) Q4 2021 Earnings Call Transcript [Mar-31-22 05:30PM] Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus [Mar-31-22 01:31PM]
10-11-2021	PM	7:00 AM ET (Nov 10)	TSHA	Taysha Gene Therapies, Inc.	590.84	-1.35	-1.02	-1.28	Taysha Gene Therapies EPS misses by $0.29 [11/10/2021 7:40 AM]	15.75	0.78 (5.21%)	15.16	0.19 (1.27%)	14.71 - 33.35	269,928	270,000	553
Taysha Gene Therapies EPS misses by $0.29 [11/10/2021 7:40 AM] Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update [Nov-10-21 07:00AM]
16-08-2021	PM	7:00 AM ET (Aug 16)	TSHA	Taysha Gene Therapies, Inc.	662.42	-1.09	-0.81	0.00	Taysha Gene Therapies EPS misses by $0.25 [8/16/2021 7:09 AM]	15.83	-1.55 (-8.92%)	17.38	0.0 (0.00%)	15.75 - 33.35	92,565	60,000	195
Taysha Gene Therapies EPS misses by $0.25 [8/16/2021 7:09 AM] Taysha Gene secures up to $100M non-dilutive term loan financing [8/16/2021 8:27 AM] Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing [Aug-16-21 07:00AM] Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update [Aug-16-21 07:03AM] Taysha Gene Therapies, Inc. (TSHA) Q2 2021 Earnings Call Transcript [Aug-16-21 07:00PM] Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development [Aug-16-21 03:04PM]
11-05-2021	PM	Before the open (May 11)	TSHA	Taysha Gene Therapies, Inc.	801.72	-0.87	-0.54	0.00	Taysha Gene Therapies EPS misses by $0.36 [5/11/2021 7:03 AM]	21.00	0.48 (2.34%)	0.0	0.0 (0.00%)	18.16 - 33.35	85,012	70,000	0
Taysha Gene Therapies EPS misses by $0.36 [5/11/2021 7:03 AM] Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021 [May-10-21 01:17PM] Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal [May-10-21 07:00AM] Taysha Gene Therapies Inc to Host Earnings Call [May-11-21 05:45AM] Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update [May-11-21 07:00AM] Taysha Gene Therapies, Inc. (TSHA) Q1 2021 Earnings Call Transcript [May-11-21 08:00PM]